ModifiedUnitedHealthcarePolicy CS029KS.02

Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Kansas Only)

Policy governs the use of cytologic examination of breast ductal fluids (ductal lavage, nipple aspirate fluid, fiberoptic ductoscopy) for breast cancer screening, diagnosis, or as tools to guide surgery in the state of Kansas; it states these are unproven and not medically necessary due to insufficient evidence.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Kansas Only)

Policy CodePolicy CS029KS.02

Change TypeRevised sections: Description of Services, Clinical Evidence, FDA, References

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionDo not pursue ductal lavage, nipple aspirate fluid cytology/ductal fluid aspiration, or fiberoptic ductoscopy for screening or diagnosis because they are considered unproven and not medically necessary in Kansas.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information and archived previous policy version CS029KS.01.

38.9%NAF samples inadequate (meta-analysis)

0.64NAF cytology sensitivity

0.97NAF cytology specificity

94%Ductoscopy pooled sensitivity (DSany)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

47%Ductoscopy pooled specificity (DSany)

Coverage Determination and Rationale

Overall coverage decision

Covered when ALL of the following are met:

Primary stance: Ductal lavage, breast ductal fluid aspiration and cytology (including nipple aspirate fluid), and fiberoptic ductoscopy are unproven and not medically necessary for breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery due to insufficient evidence of efficacy and diagnostic limitations.

Policy applies to Kansas only (see Application).

Supporting rationale — ductal lavage: Evidence does not demonstrate benefit: DL has low sensitivity, a high percentage of inconclusive results, and no evidence of improved breast cancer mortality when added to standard screening; practice guidelines (NCCN) do not recommend DL.

See studies and guideline statements noting insufficient evidence and recommendation against routine use.

Supporting rationale — nipple aspirate fluid (NAF) cytology: NAF cytology has limited diagnostic accuracy (pooled sensitivity ~0.64, specificity ~0.97) and a high rate of inadequate samples (mean 38.9%), limiting clinical utility; insufficient evidence that NAF collection leads to earlier detection or improved survival.

Supporting rationale — fiberoptic ductoscopy (FDS): FDS evidence is limited to preliminary studies of technical feasibility and diagnostic accuracy; the procedure is technically challenging, examines only a small portion of the ductal system, and there is no high-quality evidence that ductoscopy improves detection rates, earlier stage diagnosis, or mortality.

Operational implication: Because these procedures are considered investigational and not medically necessary in Kansas, services may be denied on that basis and inclusion of CPT 19499 in coding reference does not imply coverage.

Providers must follow applicable benefit plan, state, or federal prior authorization rules.

The following procedures are considered unproven and not medically necessary for breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery in Kansas: breast ductal lavage, breast ductal fluid aspiration and cytology (including nipple aspirate fluid), and fiberoptic ductoscopy. Evidence is insufficient to demonstrate clinical benefit for these procedures, and they may be denied on that basis.

Informational: FDA approval alone is not a basis for coverage. In addition, the FDA has stated that nipple aspirate tests are not substitutes for mammograms, and providers should not use such tests in place of recommended mammographic screening.

Summary: ductal lavage (DL), nipple aspirate fluid/ductal fluid cytology or aspiration (NAF), and fiberoptic ductoscopy (FDS) are considered investigational/unproven and are not covered. The evidence shows low sensitivity, high rates of inadequate or inconclusive samples, limited anatomic sampling, and no demonstrated improvement in cancer detection outcomes or mortality to support routine clinical use.

Applicable Codes

Applicable CPT Codes (reference)CPT

19499

Unlisted procedure, breast

Provider Requirements and Billing Guidance

Denial Risk

Prior authorization / coverage implication

These procedures are considered unproven and not medically necessary for breast cancer screening, diagnosis, or as alternatives to guide surgery. As a result, prior authorization does not make them medically necessary and services may be denied.

Breast ductal lavage
Breast ductal fluid aspiration and cytology
Fiberoptic ductoscopy (with or without ductal lavage)

Prior Authorization

Prior authorization: follow plan-specific rules

Providers must follow applicable benefit plan, state, and contractual rules when requesting prior authorization and submitting claims. Check member-specific benefits and any applicable state mandates.

Follow the member’s specific benefit plan terms

Background and Scope

Background: Cytologic examination of epithelial cells from breast ductal fluids (obtained via ductal lavage or nipple aspiration) and direct intraductal visualization with fiberoptic ductoscopy have been studied as potential early indicators of breast cancer or as adjuncts to guide surgery. Published studies and systematic reviews report important limitations: DL and NAF cytology have low sensitivity, frequent inadequate or inconclusive samples (for NAF a mean inadequate sample rate of 38.9% is reported), and no evidence of improved breast cancer mortality or proven clinical benefit. FDS evidence is largely preliminary and technical, is limited to small cross‑sectional studies, examines only a small portion of the ductal system, and has not demonstrated improved detection, earlier stage at diagnosis, or mortality benefit. Guideline panels do not recommend routine use and further longitudinal outcome studies would be required to validate clinical utility.

Definitions and Procedure Descriptions

Ductal lavage (DL)

TermDuctal lavage (DL)

DefinitionAn invasive procedure that removes ductal fluid by inserting a microcatheter into the breast ducts via the nipple.

Use/notesObtains epithelial cells from ductal fluid for cytologic or biomarker analysis as a proposed early indicator of breast cancer; considered technically invasive compared with nipple aspiration.

Nipple aspirate fluid (NAF)

TermNipple aspirate fluid (NAF)

DefinitionFluid obtained from the nipple either noninvasively or via fine-needle aspiration for cytologic or biomarker analysis.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Kansas Only)

Policy CodePolicy CS029KS.02

Change TypeRevised sections: Description of Services, Clinical Evidence, FDA, References

Effective DateAug 1, 2025

Next Review DateN/A

SourceLink

On This Page

Comply with applicable state law and contractual requirements

Step Therapy

No step therapy requirements specified

No step therapy requirements are specified in this policy. This is informational only; follow plan-specific rules if any step edits apply.

Documentation Required

Policy use and contractual checks

Providers should verify federal, state, and contractual benefit plan requirements prior to using this policy. The terms of the federal, state, or contractual requirements govern when they differ from this Medical Policy.

Check member-specific benefits and plan documents
When conflicts exist, benefit plan terms govern coverage determination

Billing Rule

Coding reference

CPT 19499 (Unlisted procedure, breast) is provided for coding reference only. Listing of this code does not imply the procedure is covered. Inclusion does not guarantee reimbursement.

CPT: 19499 — Unlisted procedure, breast

Note

(Provider action placeholder)

This is a reminder to the writer to check source materials for any additional provider instructions or plan-specific requirements that may not be summarized here.

Denial Risk

Not medically necessary procedures

DL, breast ductal fluid aspiration/cytology, and fiberoptic ductoscopy are unproven and not medically necessary for screening, diagnosis, or surgical guidance. Do not submit prior authorization requests expecting these to meet medical necessity.

Documentation Required

Benefit/Contractual Requirements Govern

Benefit plan terms, federal or state laws, and contractual requirements may supersede this Medical Policy. Verify and follow those requirements when they differ from this policy.

Benefit/Contractual requirements govern when they differ from this Medical Policy

Use/notesCollected as a sample for cytologic assessment and may be combined with image analysis or mammary ductoscopy specimens in research assessing cancer detection accuracy.

Fiberoptic ductoscopy (FDS)

TermFiberoptic ductoscopy (FDS)

DefinitionUse of a very thin endoscope to directly visualize breast ducts (intraductal endoscopy).

Use/notesCan be performed with aspiration cytology, biopsy, or intraoperative techniques (eg, methylene blue injection) to evaluate abnormal nipple discharge or localize intraductal lesions; technically challenging and examines only a small portion of the ductal system.

NAF — cytology and image analysis

TermNAF cytology and image analysis

DefinitionCytologic examination of cells in nipple aspirate fluid sometimes combined with image (aneuploidy) analysis to improve detection accuracy.

Evidence/notesIn Sauter et al. (2010), combining NAF cytology with MD cytology and image analysis increased sensitivity (up to 55%) while maintaining high specificity (100%) in select cohorts, but study limitations include small sample size and potential false positives with pathologic nipple discharge.

FDS — endoscopic intraductal visualization

TermFDS — endoscopic intraductal visualization

DefinitionAn endoscopic intraductal visualization technique that directly inspects breast ducts to diagnose or localize intraductal lesions.

Use/notesMay be used with intraoperative localization methods (eg, methylene blue injection) and can detect intraductal lesions in patients with pathologic nipple discharge, but is technically difficult, examines only part of the ductal system, and lacks high-quality evidence demonstrating improved detection or outcome benefits.